Daxxify (prabotulinumtoxin-A) lasts approximately 6 months per treatment cycle, roughly double Botox's standard 3-month duration. This extended interval is Daxxify's primary clinical and marketing advantage—patients return half as often, which appeals to those seeking convenience and predictability. Botox, however, remains the category standard for unit potency, pricing, and practitioner familiarity, and its shorter cycle offers flexibility that many practices and patients actually prefer.
Injectables
Daxxify vs Botox: Duration, Cost, and When to Use Each
Daxxify's 6-month duration commands a premium, but Botox's 3-month cycle and lower cost make it the right choice for many practices and patients.
| Compared | Botox | Daxxify |
|---|---|---|
| Typical duration | 12–16 weeks (3–4 months) | 24 weeks (5–7 months real-world) |
| Onset | 3–7 days to visible effect | 3–7 days to visible effect |
| Wholesale cost per unit | $12–16 per unit | $18–24 per unit |
| Typical treatment units (glabellar/forehead) | 20–25 units | 20–25 units |
| FDA status | FDA-cleared for glabellar lines | FDA-cleared for glabellar lines |
| Annual patient appointments | ~4 per year | ~2 per year |
| Best for | First-time users, budget-conscious, variable metabolism, appointment frequency | Convenience-seekers, frequent travelers, stable responders, rural practices |
| Clinical efficacy at equivalent units | Category standard; identical mechanism | Identical mechanism; duration advantage only |
| Downtime | Minimal; same-day return to activity | Minimal; same-day return to activity |
A Botox patient generates 4 appointments annually; Daxxify generates 2—a revenue-per-patient trade-off worth modeling before committing inventory.
Daxxify's longevity stems from its peptide-linker formulation, which delays clearance of the toxin-SNARE complex. Clinical trials showed median duration of 24 weeks; real-world data from practices now reporting 5–7 months depending on patient metabolism and muscle mass. Botox typically plateaus at 12–16 weeks, though some patients—particularly those with lower metabolism or lighter musculature—report 4 months.
This gap matters operationally. A patient on Botox generates 4 appointments annually; Daxxify generates 2. For high-volume practices, that's a scheduling and revenue-per-patient trade-off worth modeling.
Cost Structure and Unit Economics
Daxxify's wholesale cost runs roughly 1.5–2× Botox's per-unit price, depending on your manufacturer contract and rebate tier (Allergan Aesthetics' Alle program vs. Revance's direct pricing). A typical Daxxify treatment uses 20–25 units for glabellar/forehead work; Botox uses the same. At current market rates:
- Botox: $12–16 per unit wholesale (varies by volume tier and loyalty program)
- Daxxify: $18–24 per unit wholesale
Your retail margin structure determines whether Daxxify's longer duration justifies the higher acquisition cost. If you charge $15–20 per unit for Botox and $22–28 for Daxxify, the per-treatment margin is similar, but annual revenue per patient drops because they visit half as often.
Patient Fit and Selection
Daxxify works best for:
- Patients with predictable, stable facial anatomy who want fewer appointments
- Those traveling frequently or with unpredictable schedules
- Patients who've had consistent, positive Botox results and want to extend intervals
- Practices in rural or underserved areas where patient travel is a barrier
- Patients willing to pay a premium for convenience
Botox remains the better choice for:
- First-time neuromodulator users (lower commitment, easier to adjust)
- Patients with variable response or metabolism concerns (3-month cycle allows rapid titration)
- Practices prioritizing appointment frequency and cash flow consistency
- Patients on tight budgets (lower per-treatment cost)
- Those wanting flexibility to adjust dose or frequency seasonally or for events
Clinical Considerations
Both are FDA-cleared for glabellar lines; both work identically on the mechanism level (SNARE-complex inhibition). Daxxify carries no clinical advantage in onset speed (both 3–7 days to visible effect) or efficacy at equivalent units. The duration difference is real but not infinite—some patients report Daxxify wearing off closer to 4–5 months, especially if they're high-metabolizers or have large muscle mass.
Cross-over from Botox to Daxxify is straightforward (unit-for-unit equivalence), though some practices report patients perceiving a slightly softer onset with Daxxify, possibly due to the formulation's different diffusion profile. This is anecdotal and not clinically validated.
Practice Economics
The key question: does extended duration drive higher patient lifetime value or lower annual revenue per patient? A patient paying $300 for Botox every 3 months ($1,200/year) generates more annual revenue than one paying $400 for Daxxify every 6 months ($800/year)—even though the Daxxify patient may perceive better value and loyalty.
Practices with strong retention and upsell (combining neuromodulator with filler, laser, or energy devices at each visit) may see Daxxify as a retention risk. Practices in competitive markets or with high patient acquisition costs may see it as a loyalty tool.
Daxxify also carries higher inventory risk: slower turnover, longer shelf life required, and lower volume adoption means less rebate leverage with Revance compared to Allergan's Alle ecosystem.
The Bottom Line
Daxxify is not superior—it's different. It solves a real problem (appointment burden) for a subset of patients and practices, but at the cost of lower appointment frequency and potentially lower annual revenue per patient. Botox's dominance reflects not clinical inferiority but economic and operational fit for the majority of practices. Most successful practices stock both, positioning Daxxify as a premium option for the right patient rather than a wholesale replacement.
Frequently asked questions
How long does Daxxify last compared to Botox?
Daxxify lasts approximately 6 months (24 weeks median, with real-world reports of 5–7 months), while Botox typically lasts 12–16 weeks (3–4 months). This means Daxxify patients need roughly half as many appointments annually—about 2 per year versus 4 for Botox.
What is the wholesale cost difference between Daxxify and Botox?
Daxxify wholesale costs roughly 1.5–2× more than Botox per unit. Current market rates are approximately $12–16 per unit for Botox and $18–24 per unit for Daxxify, depending on your volume tier and manufacturer contract (Allergan's Alle program versus Revance direct pricing).
Should I offer Daxxify or Botox to first-time patients?
Botox is the better choice for first-time neuromodulator users because it carries lower commitment, allows easier dose adjustment within a 3-month cycle, and costs less per treatment. Daxxify works best for established patients who've had consistent Botox results and want to extend their appointment intervals.
Does Daxxify work faster than Botox?
No. Both Daxxify and Botox have identical onset speed of 3–7 days to visible effect and work through the same mechanism (SNARE-complex inhibition). The only meaningful difference is duration, not speed or efficacy at equivalent unit doses.
How many units of Daxxify do I need for forehead and glabellar lines?
Daxxify uses the same unit dosing as Botox—typically 20–25 units for combined glabellar and forehead treatment. The conversion is unit-for-unit equivalent when switching patients from Botox to Daxxify.
Will offering Daxxify increase my practice revenue?
Not necessarily. While per-treatment margins may be similar (charging $22–28 per Daxxify unit versus $15–20 for Botox), annual revenue per patient actually drops because they visit half as often. The trade-off is better patient retention and convenience, which may offset lower appointment frequency in your market.
Free weekly brief
Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.